Evidence map›Paper›PMID 41531505›Full record

ArticleOpen forum infectious diseases2026

Compassionate Use of Olorofim for Invasive Mold Infections: A Nationwide Observational Study in France.

V Esnault, C Godet, D Garcia-Hermoso, A Charmillon, P Parize, C Bonnal, A Debourgogne, F Morio, M E Bougnoux, E Dannaoui and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Endocarditis Due toOpen forum infectious diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

V EsnaultInfectious Diseases Department, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.ORCID https://orcid.org/0000-0002-6960-6700
C GodetService de Pneumologie et Oncologie Thoracique, Centre Constitutif Maladies Pulmonaires Rares, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France.
D Garcia-HermosoInstitut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Département de Mycologie, Université Paris Cité, Paris, France.ORCID https://orcid.org/0000-0001-5288-2904
A CharmillonInfectious Diseases Department in Charge of Mobile Infectiology Team, CHRU de Nancy-Brabois,Vandoeuvre-lès-Nancy, France.ORCID https://orcid.org/0000-0002-8492-9321
P ParizeNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0002-0786-7518
C BonnalParasitology and Mycology Department, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France.ORCID https://orcid.org/0000-0003-3030-5318
A DebourgogneStress, Immunity, Pathogens Laboratory, Faculty of Medicine, EA7300 Lorraine University, Vandoeuvre-lès-Nancy, France.ORCID https://orcid.org/0000-0002-1240-856X
F MorioParasitology and Mycology Department, Nantes University Hospital, UR1155-IICiMed, Nantes Université, Nantes, France.ORCID https://orcid.org/0000-0002-5859-6105
M E BougnouxParasitology and Mycology Laboratory, Necker University Hospital, Paris, France.ORCID https://orcid.org/0000-0003-4721-2740
E DannaouiParasitology and Mycology Laboratory, Necker University Hospital, Paris, France.ORCID https://orcid.org/0000-0002-2817-3830
A P BellangerParasitology and Mycology Department, Besançon University Hospital, UMR 6249 CNRS Chrono-Environnement, Univ Franche-Comté, Besançon, France.ORCID https://orcid.org/0000-0003-4144-476X
J P GangneuxEHESP, Institut de Recherche en Santé, Environnement et Travail, Inserm UMR-S1085, Univ Rennes, CHU Rennes, Rennes, France.ORCID https://orcid.org/0000-0002-4974-5607
B SendidLaboratory of Mycology and Parasitology, Inserm, U1285-CNRS UMR8576 "Glycobiology in Fungal Pathogenesis & Clinical Applications" Inserm, U1285-CNRS UMR8576, Hospital and University of Lille, Lille, France.ORCID https://orcid.org/0000-0003-1577-7325
E CardotService de Biologie Clinique, Hôpital Foch, Suresnes, France.ORCID https://orcid.org/0000-0002-0340-6300
C MelenotteNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-3159-1061
C RouzaudNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
A LefortDepartment of Internal Medicine, Beaujon Hospital, AP-HP, Clichy, France.ORCID https://orcid.org/0000-0002-4507-6426
S Colin de VerdiereCentre de Transplantation Pulmonaire et CRCM, Hôpital Foch, Suresnes, France.ORCID https://orcid.org/0009-0007-4854-8955
O BrugiereCentre de Transplantation Pulmonaire et CRCM, Hôpital Foch, Suresnes, France.ORCID https://orcid.org/0000-0002-1513-1957
M TetartDepartment of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France.ORCID https://orcid.org/0000-0001-6723-8089
E EschapasseService de Pneumologie, L'Institut du Thorax, Hôpital Guillaume et René Laënnec, Centre Hospitalier Universitaire de Nantes, Nantes, France.ORCID https://orcid.org/0000-0001-6900-6783
A BerceanuHematology Department, Besançon Hospital, Besançon, France.
P TattevinInfectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.ORCID https://orcid.org/0000-0003-3617-5411
R LevyPediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital for Sick Children, AP-HP, Paris Cité University, Imagine Institute, Paris, France.
E FaureInfectious Diseases Department, CNRS, Inserm, Institut Pasteur Lille, U1019-UMR 9017-CIIL (Center for Infection and Immunity of Lille), CHU Lille, Université de Lille, Lille, France.ORCID https://orcid.org/0000-0003-2787-0885
F LanternierInstitut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Département de Mycologie, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increasing incidence of resistant invasive mold infections (IMIs) has highlighted the need for novel antifungal agents. Olorofim, a first-in-class orotomide, has shown promising efficacy in a recent phase II study, but clinical data remain limited. Methods: We conducted a retrospective multicenter cohort study in France, including all patients who received olorofim under compassionate use for proven or probable non-Mucorales IMIs. Eligible patients had IMIs refractory to or intolerance to standard antifungals or no effective treatment options. Efficacy was defined as mycological and clinical control of infection; safety was also assessed. Results: Between January 2020 and December 2023, 17 patients (median age, 39 years) received olorofim. Underlying conditions included primary immunodeficiency (n = 4) and lung transplantation (n = 5). Sites of infection included the lung (88.2%) and the central nervous system (23.5%), with 5 cases of disseminated disease. In total, 23 strains were identified, mostly Conclusions: Olorofim exhibited potential efficacy and good tolerability in patients with refractory IMIs. Further data from ongoing clinical trials are needed to confirm these findings.

Indexed as

antifungal agentsfungal diseasesfungal infectionsinvasive pulmonary aspergillosisolorofim

Identifiers

PMID41531505
PMCPMC12794007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.